All News
What biomarker do you think is the most important in diagnosis of Macrophage Activation Syndrome/ secondary HLH @rheumnow #ACR20
Bella Mehta bella_mehta ( View Tweet)
@RheumNow #acr20 abs0098 CCL2&CCR2 may play role in inflammatory response in AOSD, high levels in active AOSD subside with six resolution. Correlate with CRP, neutrophil count& ferritin levels. Does not correlate w/ Clincial markers of disease activity
Olga Petryna DrPetryna ( View Tweet)
Interim analysis of the RELIANCE registry studying effect of canakinumab (CAN) in 80 patients w/ febrile CAPS. Efficacy of CAN assessed w/ AIDA (inflam index) showing ~70% were in low activity (<9) @ACR20 Abstr#1479 https://t.co/UC2eJbpVLM https://t.co/M71s8gXZY9
Dr. John Cush RheumNow ( View Tweet)
Mitigating Immunogenicity When Using Uricase Therapies as ULT
ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of biological effects.
Read Article
Crystal Arthritis and Gout Highlights at ACR: Dr. Nicola Dalbeth
Gout specialist Dr. Nicola Dalbeth from Aukland, New Zealand provides a preview perspective on crystal arthritis and gout studies and sessions at #ACR20.
https://t.co/QfVSpeVXlf https://t.co/cBwKF5P5eb
Links:
Dr. John Cush RheumNow ( View Tweet)
Autoimmune Disease Outcomes of Women with Breast Implants: A Population-Based Study https://t.co/Z6R8zRezfN #breastimplants #IMID an old chestnut
Peter Nash drpnash ( View Tweet)
Reducing Immunogenicity of Pegloticase (RECIPE) w/ concomitant use of MMF in pts w/ refractory gout is a phase II double blind RCT that shows sustained serum urate lowering effect in addition to decrease in monthly rate of flares. #ACRbest #Abst0952 @RheumNow Practice changing? https://t.co/Z7GwCXZftE
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Next up! #Autoinflammatory diseases: mechanisms and management. First: CRMO & SAPHO with Dr. Polly Ferguson
Highlights:
📍The *many* names of CRMO/CNO
📍Clinical features
📍Rx options (NSAIDs, bisphosphonates, TNFi)
📍Role of innate immunity in etiology
#ACRambassador https://t.co/qP3IySJKGC
Danny Soulsby dsoulsMD ( View Tweet)
Genotype analysis define new illnesses such as VEXAS.
”Somatic mutation may account for a significant fraction of adult-onset inflammatory disease” says Dr. Dan Castner.
Science enthusiasm at 3S038. Autoinflammatory Diseases.
@petercgrayson #ACR20 <TK https://t.co/gyTxF8NWtO
ARD & RMD Open ARD_BMJ ( View Tweet)
Fascinating and engaging talk by Dr. Kastner on the discovery of VEXAS using a genotype-first strategy. Definitely one to go back and watch if you missed it! #ACR20 https://t.co/D090V7HiG2
E. Sloan esloanmd ( View Tweet)
Dan Kastner giving an absolute tour de force of the discovery of VEXAS in autoinflammatory diseases: mechanisms and management session now. If you aren't listening, watch it back! #ACR20 @rheumnow https://t.co/zell5e2Brt
Richard Conway RichardPAConway ( View Tweet)
Excellent session on #autoinflammatory syndromes #SAPHO syndrome -IL-1 role in disease pathogenesis and something that I ve not come across clinically #Majeed Syndrome @RheumNow #ACR20 #3S038 https://t.co/vnfjPD6Zx9
Bella Mehta bella_mehta ( View Tweet)
Dr Merriman presents on role of diet in gout. It is minor, especially compared to urate lowering therapy. Average attributable fraction approximately 10-fold greater for ULT than following healthy-eating guidelines. @rheumnow #ACR20 Abstr#951 https://t.co/1tftswOEJq
Richard Conway RichardPAConway ( View Tweet)
Dr Cai presents risk of CVD in gout in study 450,000 patients. Gout was independently associated with an increased risk of CVD events HR = 1.24 for women; 1.21 for men. @rheumnow #ACR20 Abstr#950 #ACRbest https://t.co/089aKtN5a7
Richard Conway RichardPAConway ( View Tweet)
@RheumNow #ACR20 abs0710 early biologic therapy (BT) in JIA: Early BT=better outcome ( 81.8% on TNFi). BT start after 7,5mo from Dx correlates w/higher probability of active disease at 2 yrs (S=0,67 E=0,63). In active group at 2y 75% arthritis, 16,7% uveitis& 8,3% both. #ACRbest
Olga Petryna DrPetryna ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Listen to part I of our #ACR20 Day 1 recap. Listen through the link below or find us on Apple podcasts.
https://t.co/W6EMQiF9Rf https://t.co/R1ieCFnIxz
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by Novartis. All content chosen by @RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Dr Peral reports on intracellular crystal containing vacuoles in gout and CPP arthritis. Crystal containing vacuoles only seen in CPP arthritis. @rheumnow #ACR20 Abstr#666 https://t.co/ITQMXhjQt0
Richard Conway RichardPAConway ( View Tweet)
Dr Vargas-Santos reported on risk of gout with SGLT2-inhibitors using THIN database. Canagliflozin shown in prior RCT to reduce gout risk. Here dapagliflozin and empagliflozin showed even stronger effect @rheumnow #ACR20 Abstr#660 https://t.co/MTjByMmHo7
Richard Conway RichardPAConway ( View Tweet)